Serum Institute to provide 20 mn Covishield doses to govt free of cost

The Serum Institute of India (SII) has offered 20 mn doses of Covishield vaccine to the central government free of cost amid a rise in Covid-19 cases in some countries, official sources said

Covishield
Photo: Shutterstock
Press Trust of India New Delhi
2 min read Last Updated : Dec 29 2022 | 12:15 AM IST

The Serum Institute of India (SII) has offered two crore doses of Covishield vaccine to the central government free of cost amid a rise in COVID-19 cases in some countries, official sources said on Wednesday.

According to an official source, Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute, has written to the Health Ministry offering the doses worth Rs 410 crore free of cost.

It is learnt that Singh has sought to know from the ministry how the delivery can be made.

SII has so far provided more than 170 crore doses of Covishield to the government for the national immunisation programme.

Amid a spike in COVID-19 cases in some countries, including China and South Korea, the government has sounded an alert and asked states and Union territories to prepare for any eventuality.

India has stepped its surveillance and genome sequencing of Covid positive samples.

With only 27 per cent of the eligible adult population having taken the precaution dose, government officials have appealed to those due for it to take it.

Official sources on Wednesday cautioned that the next 40 days will be crucial as India may see a Covid surge in January.

Even if there is a wave, deaths and hospitalisation will be very low, the Health Ministry sources said.

The government made random coronavirus testing mandatory for two per cent of passengers arriving in each international flight from Saturday.

Prime Minister Narendra Modi and Health Minister Mansukh Mandaviya have held meetings to assess the country's preparedness to deal with a fresh surge in cases.

Mock drills were held at health facilities across India on Tuesday to check operational readiness to deal with any spurt in COVID-19 infection.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusSerum Institute of Indiacentral government

First Published: Dec 28 2022 | 7:33 PM IST

Next Story